The 9 analysts offering 12-month price forecasts for Amicus Therapeutics Inc have a median target of 16.00, with a high estimate of 29.00 and a low estimate of 12.00. The median estimate represents a +48.70% increase from the last price of 10.76.
The current consensus among 11 polled investment analysts is to Buy stock in Amicus Therapeutics Inc. This rating has held steady since September, when it was upgraded from a Hold rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.18
Reporting Date Nov 08
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.